• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Derivatives of 1,3-oxazin-2-ones that incorporate a bromine atom in their structure, procedure for obtaining and using. Due to their biological activity in the treatment of diseases and their usefulness in Organic Synthesis, oxazinones are currently the object of study and different synthesis methods have been proposed. The present invention proposes a method of synthesis of oxazinones from N-alenylcarbamates that allows the incorporation of a bromine atom in its structure, which would present a synthetic advantage since it would allow the subsequent functionalization of these substrates in order to obtain oxazinones functionalized with potential biological and/or pharmacological activity. The method allows the cyclization mode to be controlled and 5-bromo-1,3-oxazin-2-ones are obtained with yields greater than 50%. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2798324A1
    申请号:ES202030527
    申请日:2020-06-04
    公开日:2020-12-10
    发明作者:Del Campo Teresa Martínez；Pinedo Mireia Toledano；Requena Pedro Almendros
    申请人:Consejo Superior de Investigaciones Cientificas CSIC；Universidad Complutense de Madrid；
    IPC主号:
    专利说明:

    [0002] Derivatives of 1,3-oxazin-2-ones that incorporate a bromine atom in their structure, procedure for obtaining and using
    [0004] TECHNICAL SECTOR
    [0006] The present invention falls within the chemical and pharmaceutical fields. More specifically, it refers to a new procedure for the preparation of brominated derivatives of 1,3-oxazin-2-ones and their uses as chemical compositions and in Organic Chemistry as key synthesis intermediates for pharmaceutical products.
    [0008] BACKGROUND OF THE INVENTION
    [0010] The 1,3-oxazin-2-one skeleton is present in various natural and non-natural products that possess biological activity for the treatment of different diseases. Among the non-natural 1,3-oxazinones, benzoxazinones are of great importance, among which is Efavirenz®. This compound is a commercial drug used in the treatment of HIV due to its activity as an inhibitor of the reverse transcriptase enzyme.
    [0012] On the other hand, oxazinones have also been shown to be useful as intermediates in Organic Synthesis (Kuznestov, N. et al. Eur. J. Org. Chem. 2012 , 334; Shapk-Kraievskyi, B. et al. Tetrahedron. 2012 , 60 , 2179). For example, the synthesis of metofolin, an analgesic of the isoquinoline family, has been carried out starting from a tricyclic 1,3-oxazinan-2-one (Richter, H. et al. Angew. Chem. Int. Ed. . 2012, 51, 8784).
    [0014] Due to their biological activity in the treatment of diseases and their utility in Organic Synthesis, oxazinones are currently being studied and different synthesis methods have been proposed.
    [0016] Thus, recently, a compound derived from 1,3-oxazinan-2-one has been synthesized effective in the fight against diabetes, since it is capable of inhibiting the enzyme 11-B-hydroxysteroid dehydrogenase type 1 (11-B-HSD1 ), implicated in this disease (Xu, Z. et al. J. Med. Chem. 2011 , 54, 6050).
    [0018] An interesting approach is the synthesis from the reaction of N-Boc-3-butyn-1-amines catalyzed by a gold salt (Robles-Machin, R. et al. J. Org. Chem. 2006 , 51, 5023 ).
    [0020] The synthesis of oxazinones from allenic carbamates has also been described. More specifically, the synthesis of 1,3-oxazinan-2-ones by oxycyclization of alenylcarbamates catalyzed by gold, with complete control of regioselectivity (Alcaide, B. et al. Beilstein J. Org. Chem. 2013 , 9, 818) .
    [0022] The cyclization of allenes with a nucleophilic substituent has the disadvantage of regioselectivity. For this reason, the development of new methods to control regioselectivity is of interest. On the other hand, the only method described in the literature for the synthesis of oxazinones from N-alenylcarbamates does not allow the incorporation of a bromine atom in its structure, which would present a synthetic advantage since it would allow the subsequent functionalization of these substrates. in order to obtain functionalized oxazinones with potential biological and / or pharmacological activity.
    [0024] EXPLANATION OF THE INVENTION
    [0025] In a first aspect, the present invention refers to derivatives of 1,3-oxazin-2-ones that incorporate in their structure a bromine atom of Formula (II) where R is an aromatic group, an alkyl or a heterocycle:
    [0032] In a preferred embodiment, the 1,3-oxazin-2-one derivatives that incorporate a bromine atom of Formula (II) in their structure are the compounds from formulas (2a) to (2e):
    [0037] Another object of the present invention constitutes a method of synthesis of 1,3-oxazin-2-ones that incorporate in their structure a bromine atom, of Formula II (where R can be aromatic, alkyl or heterocycles groups) through a reaction of cyclization of alenyl-carbamates of general formula (I) promoted by CuBr 2 so that it is possible to control the cyclization mode and obtain potentially interesting molecules from the biological point of view.
    [0039] The cyclization reaction of the alenyl carbamates of formula I is carried out following the reaction of Scheme 1 under different conditions, using different promoters, solvents and temperatures.
    [0042] As starting substrates, the W-alenylcarbamates of formula (1a) to (1e) are used, which are easily prepared following the procedure described in the literature (Alcaide, B. et al. Beilstein J. Org. Chem. 2013 , 9, 818):
    [0047] The abbreviations used in this document are as follows:
    [0048] Ph phenyl functional group
    [0049] Boc tert-butyloxycarbonyl
    [0050] (Boc) 2nd di-tert-butyl dicarbamate
    [0051] Me methyl
    [0052] MeO methoxy
    [0053] PMP p-methoxyphenyl
    [0054] t.a. room temperature
    [0055] T Temperature
    [0056] t time
    [0058] The cyclization reaction of the W-alenylcarbamates of formula (1a) to (1e) is carried out using different promoters, solvents and temperatures.
    [0060] Copper bromide (CuBr 2 ) is used as a promoter in the presence of a solvent.
    [0062] In a preferred embodiment, the solvent is MeCN or MeNO2 and the cyclization is carried out at room temperature or at a higher temperature up to 70 ° C for a reaction time between 1.5 and 24 hours. Most preferably, the solvent is refluxing MeNO2.
    [0063] In these cases, starting from compounds 1a to 1e, 5-bromo-1,3-oxazin-2-ones of formula (2a) to (2e) are obtained with yields greater than 50%.
    [0068] These bromine derivatives are interesting from the synthetic point of view due to the possibility of functionalizing the brominated position in order to obtain products with interesting pharmacological and biological properties, through a novel radical process.
    [0070] Its chemical structure allows, in another aspect of the present invention, its use in the preparation of a drug or pharmaceutical composition for the treatment and prevention of diseases such as cancer, autoimmune diseases, infectious diseases and, in general, any disease whose treatment or prevention is capable of benefiting from the biological activities shown by the compounds described in the present invention, either to a derivative thereof, or to a pharmaceutically acceptable prodrug thereof.
    [0072] Another aspect of the invention relates to the use of the compounds as pesticides in the prevention and control of pests. Examples of pests in which the compounds of the present invention may have a controlling effect include acarids, insects, and small pest animals.
    [0073] Another aspect of this invention relates to the use of the bromine derivatives described in supramolecular chemistry and / or in the elaboration of new materials, molecular probes, fluorescent probes, optical sensors and / or chemical sensors, preferably in the preparation of polymers and / or or dendrimers and, in general, of any material whose preparation is likely to benefit from the methodology shown for the compounds described in the present invention, or to a derivative thereof.
    [0075] The compounds of the present invention represented by Formula (II) can include isomers, depending on the presence of multiple bonds (eg Z, E), including optical isomers or enantiomers, depending on the presence of chiral centers. Individual isomers, enantiomers or diastereomers or mixtures thereof fall within the scope of the present invention, that is, the term isomer also refers to any mixture of isomers, such as diastereomers, racemics, etc., even their isomers optically active ingredients or mixtures in different proportions thereof. The individual enantiomers or diastereomers, as well as their mixtures, can be separated by conventional techniques.
    [0077] The term "derivative" as used herein includes both pharmaceutically acceptable compounds, that is, derivatives of compounds of Formula (II) that can be used in the manufacture of a medicine, and pharmaceutically unacceptable derivatives since these can be useful in the preparation of pharmaceutically acceptable derivatives The nature of the pharmaceutically acceptable derivative is not critical, as long as it is pharmaceutically acceptable.
    [0079] Also within the scope of this invention are prodrugs of the compounds of Formula (II).
    [0081] PREFERRED EMBODIMENT OF THE INVENTION
    [0083] The present invention is illustrated by the following examples, which are not intended to be limiting of its scope.
    [0084] Example 1.
    [0085] This example refers to the preparation of the starting alkynyl carbamates.
    [0087] Aromatic aldehydes are reacted with propargylamine in the presence of magnesium sulfate at room temperature, obtaining imines which are subsequently reduced with sodium borohydride according to scheme 2 to give amines.
    [0091] 15h Ar, 30 min.
    [0092] Scheme 2
    [0094] The protection of the NH group is carried out with di-tert-butyl dicarbamate in the presence of triethylamine as a base, obtaining the alkynyl carbamates according to Scheme 3.
    [0098] Scheme 3
    [0100] Table 1 shows the starting aldehydes, the intermediate amines and the alkynyl carbamates obtained, as well as the corresponding yields.
    [0102] Table 1
    [0104]
    [0106] n
    [0107] Example 2.
    [0108] This example refers to the preparation of the alenyl carbamates.
    [0110] The production of alenyl carbamates is carried out from alkynyl carbamates by the Crabbé reaction. For this, the alkynyl-carbamates are reacted in the presence of CuBr, paraformaldehyde and diisopropylamine, using 1,4-dioxane as solvent as shown in Scheme 4, thus obtaining the alenylcarbamates shown in Table 2, with good returns.
    [0115] Scheme 4
    [0120] CuBr (0.5 mmol), (CH 2 O) n (2.55 mmol) and diisopropylamine (1.8 mmol) were added to a solution of the corresponding alkyne (1 mmol) in 1,4-dioxane (5 ml) , in that order, and stirred under reflux under argon atmosphere. When the reaction was complete (tcf), water was added and extracted with AcOEt. The organic phases were pooled and washed with brine. It was dried with MgSO 4 and the solvent was evaporated under reduced pressure. The products obtained were purified by column chromatography on silica gel (hexane / AcOEt).
    [0121] Alenyl-carbamate 1a.
    [0123] 1H-NMR (300 MHz, CDCI 3 ): 1.51 (s, 9H, 3 CH 3 Boc), 3.79 (s broad, 2H, N-CH 2 ), 4.48 (s, 2H, CH 2 -C = =), 4.78 (dt, 2H, J = 6.6, 2.6 Hz, = = CH 2 ), 5.12 (s broad, 1H, CH ==), 7.34 (m, 5H, Ar). 13C-NMR (75 MHz, CDCI 3 ): 202.1 (= =), 158.9 (C = O), 130.8 (C4ary), 128.4 (4CH Ph), 127.1 (CH Ph), 86.9 (CH = =), 80.0 ( C4ary Boc), 76.1 (= = CH 2 ), 49.4 (CH 2 ), 44.9 (CH 2 ), 28.4 ( 3 CH 3 Boc).
    [0124] IR (CHCI 3 ): 1955 (==), 1692 (C = O) cm -1.
    [0126] HRMS (ES): Calculated M + for C 16 H 21 NO 2 : 259.1572 Experimental: 259.1579
    [0128] Alenyl-carbamate 1b.
    [0130] 1H-NMR (300 MHz, CDCI 3 ): 1.49 (s, 9H, 3 CH 3 Boc), 3.76 (s broad, 2H, N-CH 2 ), 3.80 (s, 3H, O-CH 3 ), 4.38 ( s, 2H, CH 2 -C = =), 4.75 (dt, 2H, J = 6.6, 2.8 Hz, = = CH 2 ), 5.08 (s broad, 1H, CH ==), 6.86 (d, 2H, J = 8.7 Hz, Ar), 7.19 (d, 2H, J = 8.1 Hz, Ar). 13C-NMR (75 MHz, CDCI 3 ): 206.3 (= • =), 158.8 (O- C4ary), 158.8 (C = O), 130.3 (C4ary), 129.4 (2CH PMP), 113.9 (2CH PMP), 86.9 (CH = =), 79.8 (C4ary Boc), 76.1 (= = CH 2 ), 55.2 (O-CH 3 ), 48.9 (CH 2 ), 44.6 (CH 2 ), 28.4 ( 3 CH 3 Boc).
    [0131] IR (CHCI 3 ): 1954 (= =), 1692 (C = O) cm -1.
    [0133] HRMS (ES): CaIcuIate M + for C 17 H 23 NO 3 : 289.1678 ExperimentaI: 289.1675
    [0135] Alenyl-carbamate 1c.
    [0137] 1H-NMR (300 MHz, CDCI 3 ): 1.34 (s, 3H, CH 3 ), 1.41 (s, 3H, CH 3 ), 1.45 (s, 9H, 3 CH 3 Boc), 3.39 (m, 2H, N -CH 2 ), 3.67 (m, 1H, N-CHH-aliene), 3.93 (m, 2H, O-CHH N-CHH-aiene), 4.02 (dd, 1H, J = 8.3, 6.2 Hz, O-CHH ), 4.25 (s broad, 1H, O-CH), 4.77 (dt, 2H, J = 6.6, 2.8 Hz, CH = = CH 2 ), 5.12 (q, 1H, J = 6.4 Hz, CH = = CH 2 ). 13C-NMR (75 MHz, CDCI 3 ): 208.8 (= • =), 151.8 (C = O), 109.1 (C4ary acetonide), 87.1 (CH = = CH 2 ), 79.9 (C4ary Boc), 76.3 (CH = = CH 2 ), 75.3 (O-CH), 67.3 (O-CH 2 ), 49.1 (N-CH 2 ), 47.3 (N-CH 2 -aIene), 28.4 ( 3 CH 3 Boc), 26.8 (CH 3 ), 25.5 (CH 3 ).
    [0139] IR (CHCI 3 ): 1957 (= =), 1694 (C = O) cm -1.
    [0141] HRMS (ES): CaIcuIate M + for C 15 H 25 NO 4 : 283.1784 ExperimentaI: 283.1786 Alenyl-carbamate 1d.
    [0143] 1H-NMR (300 MHz, CDCI 3 ): 1.49 (s, 9H, 3 CH 3 Boc), 3.35 (dd, 1H, J = 14.4, 7.2 Hz, N-CHH), 3.63 (s, 3H, O-CH 3 ), 3.74 (m, 1H, N-CHH), 3.77 (s, 3H, O-CH 3 ), 3.78 (m, 1H, CHHC = • =), 3.82 (d, 1H, J = 4.4 Hz, HC -N), 4.46 (m, 1H, CHH-C ==), 4.56 (d, 1H, J = 5.1 Hz, HC-O), 4.76 (m, 2H, = = CH 2 ), 5.03 (s broad, 1H, CH ==), 6.85 (d, 2H, J = 8.3 Hz, PMP), 7.44 (m, 2H, PMP). 13C-NMR (75 MHz, CDCI 3 ): 208.5 (==), 164.5 (C = O lactam), 155.7 (C = O Boc), 130.4 (C4ary), 118.7 (2CH PMP), 114.3 (2CH PMP), 87.4 (CH ==), 82.5 (HC-O), 80.5 (O-C4ary), 79.9 (== CH 2 ), 59.1 (O-CH 3 ), 55.9 (HC-N), 55.4 (O-CH 3 ), 47.4 (N-CH 2 ), 45.1 (N-CH 2 ), 28.4 ( 3 CH 3 Boc).
    [0145] IR (CHCI 3 ): 1957 (==), 1754 (C = O), 1694 (C = O) cm -1.
    [0147] NMR spectra. The 1H-NMR and 13C-NMR spectra were performed on Bruker Avance 300 (300 MHz) instruments, using TMS as an internal reference. Chemical shifts are expressed in ppm (5) and coupling constants in Hz. The multiplicity of the signals is expressed as follows: singlet (s), doublet (d), triplet (t), multiplet (m), doublet of doublets (dd), doublet of triplets (dt), quadruplet (q), septuplet (sept).
    [0148] Mass spectrometry. The high resolution electrospray (EE) mass spectra were performed at CENQUIOR (CSIC) on an AGILENT 6520 Accurate-Mass QTOF LC / MS spectrometer.
    [0150] Example 3
    [0152] This example concerns the optimization of the cyclization conditions of the alenylcarbamates.
    [0154] Starting from the alenyl-carbamate of formula 1a, the cyclization reaction according to Scheme 5 is carried out, in an inert atmosphere of argon (Ar), using CuBr 2 as promoter with different solvents, temperatures and reaction times.
    [0158] Scheme 5
    [0159] Table 3 shows the reaction conditions in each case and it is observed that the best performance resulted using CuBr 2 as promoter, MeNO 2 as solvent and reflux, at a temperature of 70 ° C; in this case, after 1.5 h of reaction, 5-bromo-1,3-oxazin-2-one (2a) was obtained as the only reaction product with a yield of 72%. This bromine derivative is interesting from the synthetic point of view due to the possibility of functionalizing this position if necessary.
    [0160] Table 3
    [0165] On a suspension of the allene (1 mmol) in nitromethane (5 mL), the CuBr 2 (2.5 mmol) was added under argon atmosphere and it was kept stirring at reflux until the reaction was complete. When the reaction ended (tcf), the solvent was evaporated under reduced pressure. The products obtained were purified by a silica gel column (hexane / AcOEt)
    [0167] Oxazinone 2a.
    [0169] 1H-NMR (300 MHz, CDCh): 3.25 (dd, 1H, J = 9.0, 6.1 Hz N-CHH-CH), 3.51 (t, 1H, J = 9.1 Hz, N-CHH-CH), 4.38 (q , 2H, J = 14.9 Hz, N-CH 2 ), 4.89 (dd, 1H, J = 9.0, 6.2 Hz, Br-CH), 5.59 (d, 1H, J = 5.6 Hz, = CHH), 6.03 (dd , 1H, J = 2.3, 1.1 Hz, = CHH), 7.26 (m, 5H, Ar). 13C-NMR (75 MHz, CDCh): 156.9 (C = O), 135.2 (= C), 129.0 (C4ary), 128.9 (2CH Ar), 128.1 (3CH Ar), 118.8 (= CH 2 ), 74.6 (Br -CH), 48.7 (CH 2 ), 48.3 (CH 2 ).
    [0170] IR (CHCh): 2929 (C = C), 1759 (C = O) cm -1. Melting point: 74-76 ° C.
    [0172] HRMS (ES): Calculated [M + H] + for C ^ H ^ BrN O 2 : 284.0105 Experimental: 284.0096
    [0173] Example 4
    [0174] This example refers to the cyclization of alenyl carbamates.
    [0175] Taking into account the optimal reaction conditions according to example 3, the products 2b to 2e are obtained according to Scheme 6.
    [0178] Scheme 6
    [0179] Table 4 shows the products and yields obtained in each case.
    权利要求:
    Claims (12)
    [1]
    1. Derivatives of 1,3-oxazin-2-ones that incorporate in their structure a bromine atom of Formula (II) where R is an aromatic group, an alkyl or a heterocycle.

    [2]
    2. Derivatives of 1,3-oxazin-2-ones that incorporate in their structure a bromine atom of Formula (II), according to claim 1, of formulas (2a) to (2e).

    [3]
    3. Process for obtaining 1,3-oxazin-2-one derivatives that incorporate in their structure a bromine atom of Formula (II), according to claim 1, which comprises the cyclization reaction of alenyl-carbamates of general Formula ( I) using copper bromide as promoter.

    [4]
    Procedure for obtaining 1,3-oxazin-2-one derivatives that incorporate in their structure a bromine atom of Formula (II), according to claim 3, where the alenyl-carbamates are compounds of formula (1a) to (1e) .

    [5]
    Procedure for obtaining 1,3-oxazin-2-one derivatives that incorporate in their structure a bromine atom of Formula (II), according to claims 3 and 4, where the cyclization is carried out in the presence of a solvent.
    [6]
    Procedure for obtaining 1,3-oxazin-2-one derivatives that incorporate in their structure a bromine atom of Formula (II), according to claim 5, where the solvent is MeCN or MeNO 2 .
    [7]
    Procedure for obtaining 1,3-oxazin-2-one derivatives that incorporate in their structure a bromine atom of Formula (II), according to claim 6, where the cyclization is carried out at room temperature or at a temperature higher than 70 ° C for a reaction time between 1.5 and 24 hours.
    [8]
    8. Process for obtaining 1,3-oxazin-2-one derivatives that incorporate in their structure a bromine atom of Formula (II), according to claim 6, where the solvent is MeNO 2 at reflux.
    [9]
    9. Use of the 1,3-oxazin-2-one derivatives as described in claims 1 or 2 for the manufacture of a drug or pharmaceutical composition for treatment and prevention of diseases selected from cancer, autoimmune diseases, and infectious diseases .
    [10]
    10. Use of the 1,3-oxazin-2-one derivatives as described in claims 1 or 2 as pesticides in the prevention and control of pests.
    [11]
    11. Use of the derivatives of 1,3-oxazin-2-ones as described in claims 1 or 2 in supramolecular chemistry.
    [12]
    12. Use of 1,3-oxazin-2-one derivatives as described in claims 1 or 2 in the preparation of new materials, molecular probes, fluorescent probes, optical sensors and / or chemical sensors, preferably in the preparation of polymers and / or dendrimers.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP3045017B2|2000-05-22|Stilbene derivatives and anticancer agents containing the same
    KR940003757B1|1994-04-30|Process for preparation of optical activated pyridobenzoxazin derivatives
    HU225294B1|2006-09-28|Oxazoline derivatives for synthesis of sidechain-bearing taxanes and preparation thereof
    FR2921060A1|2009-03-20|Preparing piperidin-3-ylamine derivative, comprises treating betaketosulfoxonium with hydrochloric acid, deprotecting amine by acid to obtain hydroxyimino-hexanoic acid, and cyclization by base, and salifying by acid
    KR900007216B1|1990-10-05|Process for prerparing disubstituted proline derivatives
    JP2020534336A5|2021-11-04|
    JP4980910B2|2012-07-18|Synthesis of benzoxazinone
    Su et al.2004|Recent advances in the chemistry of trichloromethyl chloroformate and bis-| carbonate
    ES2206738T3|2004-05-16|PROCEDURES AND INTERMEDIARIES FOR THE PREPARATION OF SUBSTITUTED DERIVATIVES OF CROMANOL.
    ES2798324B2|2021-05-19|Derivatives of 1,3-oxazin-2-ones that incorporate a bromine atom in their structure, procedure for obtaining and using
    RU2182908C2|2002-05-27|Stereoisomeric indole compounds, method of their synthesis and their using
    HU0300154A2|2003-05-28|Method for the production of spirocyclic tetronic acid derivatives
    CZ9901223A3|2002-10-16|Pentaerythritol derivative, process of its preparation and intermediates for its preparation
    JPWO2019069889A1|2020-09-10|Parasitic plant germination regulator
    US6348616B1|2002-02-19|Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
    MX2014009309A|2014-11-10|Method for preparing compound by novel michael addition reaction using water or various acids as additive.
    TW202136222A|2021-10-01|Efficient process for making 6-carboxy benzoxazole derivatives
    KR0145402B1|1998-07-15|Process for preparing of |2-benzoyl-3-c silyloxyprop-2|-yl) aminoacrylatederivatives
    KR0142139B1|1998-07-01|Method of preparation for |2-benzoyl-3-[|-yl)amino]-acrylate derivatives
    KR20210032950A|2021-03-25|Chemical method for preparing phenylpiperidinyl indole derivatives
    HU201516B|1990-11-28|Process for producing 2-cyano-2-oximinoacetamide derivatives
    KR100418327B1|2004-02-11|New aziridine derivatives and their preparation methods
    WO2019135243A1|2019-07-11|Methods for preparation of jasmonate compounds
    US4150034A|1979-04-17|Process for the preparation of substituted-phenyl-N-alkyl-carbamates
    KR0142140B1|1998-07-01|Method of preparation for 2-benzoyl-3-aminoacrylate derivatives
    同族专利:
    公开号 | 公开日
    ES2798324B2|2021-05-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2020-12-10| BA2A| Patent application published|Ref document number: 2798324 Country of ref document: ES Kind code of ref document: A1 Effective date: 20201210 |
    2021-05-19| FG2A| Definitive protection|Ref document number: 2798324 Country of ref document: ES Kind code of ref document: B2 Effective date: 20210519 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES202030527A|ES2798324B2|2020-06-04|2020-06-04|Derivatives of 1,3-oxazin-2-ones that incorporate a bromine atom in their structure, procedure for obtaining and using|ES202030527A| ES2798324B2|2020-06-04|2020-06-04|Derivatives of 1,3-oxazin-2-ones that incorporate a bromine atom in their structure, procedure for obtaining and using|
    [返回顶部]